These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 35599270)

  • 21. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    Kim JW; McKay RR; Radke MR; Zhao S; Taplin ME; Davis NB; Monk P; Appleman LJ; Lara PN; Vaishampayan UN; Zhang J; Paul AK; Bubley G; Van Allen EM; Unlu S; Huang Y; Loda M; Shapiro GI; Glazer PM; LoRusso PM; Ivy SP; Shyr Y; Swisher EM; Petrylak DP
    J Clin Oncol; 2023 Feb; 41(4):871-880. PubMed ID: 36256912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
    Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
    J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    Clarke NW; Armstrong AJ; Thiery-Vuillemin A; Oya M; Shore N; Loredo E; Procopio G; de Menezes J; Girotto G; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Virizuela JA; Emmenegger U; Navratil J; Buchschacher GL; Poehlein C; Harrington EA; Desai C; Kang J; Saad F
    NEJM Evid; 2022 Sep; 1(9):EVIDoa2200043. PubMed ID: 38319800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
    Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Váradi A; Kói T; Lang Z; Ács N; Kopa Z; Hegyi P; Hadaschik B; Grünwald V; Nyirády P; Szarvas T
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):665-672. PubMed ID: 36509931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
    Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS
    Eur Urol; 2023 Jan; 83(1):15-26. PubMed ID: 36055895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
    Yang Z; Ni Y; Zhao D; Zhang Y; Wang J; Jiang L; Chen D; Wu Z; Wang Y; He L; Shi Y; Zhou F; Zeng H; Li Y
    BMC Cancer; 2021 Aug; 21(1):919. PubMed ID: 34388965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.
    Ditonno F; Bianchi A; Malandra S; Porcaro AB; Fantinel E; Negrelli R; Ferro M; Milella M; Brunelli M; Autorino R; Cerruto MA; Veccia A; Antonelli A
    Clin Genitourin Cancer; 2024 Apr; 22(2):402-412.e17. PubMed ID: 38281877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches.
    Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
    JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
    Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study.
    Du XX; Dong YH; Zhu HJ; Fei XC; Gong YM; Xia BB; Wu F; Wang JY; Liu JZ; Fan LC; Wang YQ; Dong L; Zhu YJ; Pan JH; Dong BJ; Xue W
    Asian J Androl; 2023; 25(2):179-183. PubMed ID: 36537376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
    Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
    Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
    Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.